Objective: Sorafenib and lenvatinib have been recommended as standard tyro sine kinase inhibitors (TKIs) for progressive radioiodine-refractory differentiated thyroid carcinoma (RR-DTC). However. their efficacy remains limited with unresolved drug resistance. Therefore. https://lecoureures.shop/product-category/mountaineering-accessoires/